-
Platelet inhibition with clopidogrel has become an important weapon against recurrent coronary events in patients with coronary artery disease. However, recent evidence shows that patient response to clopidogrel is variable, with some patients having suboptimal inhibition of platelet aggregation.
-
-
-
Ongoing safety review of tiotropium; raloxifene reduces the risk of endometrial cancer; one-day treatment with famciclovir may be as effective as 3-day treatment with valacyclovir; new Clinical Practice Guideline from the American College of Physicians regarding pharmacologic treatment for low bone density and osteoporosis; FDA Actions.
-
Capecitabine and oxaliplatin were used in combination for patients with advanced pancreatic cancer refractory to first-line gemcitabine.
-
Sorafenib is a multikinase inhibitor approved for treatment of renal cell and hepatocellular carcinomas.
-
In a retrospective analysis of 323 patients with multiple myeloma, of which 169 patients received one or another form of ESA for treatment of disease or treatment-associated anemia, multivariate analysis, using a proportional hazard model, indicated worse progression-free and overall survival associated with ESA treatment.
-
Long-term disease control remains an elusive target for mantle cell lymphoma (MCL), even after aggressive therapy.
-
In the early civil cases litigated under the law in the 1990s, the courts held that EMTALA's duty to stabilize continued to apply throughout the patient's entire stay in the hospital, no matter how long it was.
-